Investigating the role of PLK4 in melanoma treatment
Functional and Therapeutic Significance of PLK4 in Melanoma
This study is looking at how a protein called PLK4 could be used to develop new treatments for melanoma, a tough type of skin cancer, to help patients find better options when current therapies aren't working.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-11001768 on NIH RePORTER |
What this research studies
This research focuses on understanding how polo-like kinase 4 (PLK4) can be targeted for treating melanoma, a challenging skin cancer. The study aims to explore the mechanisms by which PLK4 interacts with other pathways involved in melanoma progression and whether it can serve as a viable target for new therapies. By examining the effects of PLK4 inhibition, the research seeks to identify potential new treatment strategies that could overcome resistance to existing therapies. Patients with melanoma may benefit from insights gained through this research, which could lead to more effective treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with melanoma, particularly those with advanced stages of the disease.
Not a fit: Patients with melanoma who have already exhausted all treatment options or those with early-stage melanoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for melanoma that improve patient outcomes.
How similar studies have performed: Recent studies have shown promise in targeting PLK4 in other cancers, suggesting potential for success in melanoma treatment as well.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Ahmad, Nihal — University of Wisconsin-Madison
- Study coordinator: Ahmad, Nihal
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.